Sacred Heart Pediatric Hospital
Dr. Marcus Vance
Department of Pediatric Cardiology & Heart Center Accepting Patients

Dr. Marcus Vance

MD, FAAP, FACC — Director of Pediatric Cardiology & Residency Program Director

Pediatric Cardiology & Congenital Heart Surgery

Pavilion for Children, Suite 402 m.vance@sacredheartpediatric.org

Biography & Clinical Philosophy

Dr. Marcus Vance is a board-certified pediatric cardiologist with over 18 years of clinical leadership. He completed his pediatric residency at Boston Children’s Hospital / Harvard Medical School and fellowship in pediatric interventional cardiology at Texas Children’s Hospital. At Sacred Heart, Dr. Vance oversees the Pediatric Residency Training Program.

Education & Medical Training

Degrees & Medical Education

  • MD with Honors — Johns Hopkins University School of Medicine
  • BS in Biomedical Engineering — Duke University

Residencies & Fellowships

  • Pediatric Residency — Boston Children’s Hospital / Harvard Medical School
  • Fellowship in Pediatric Cardiology — Texas Children’s Hospital

Clinical Research & Academic Inquiries

Transcatheter pulmonary valve replacement and simulation-based resident medical education.

Sacred Heart Journal Publications (1)

Browse In Repository
Pediatric Cardiology March 2026

Outcomes of Transcatheter Pulmonary Valve Replacement in Pediatric Patients with Repaired Tetralogy of Fallot: A 10-Year Single-Center Retrospective Cohort

Objective: To evaluate long-term hemodynamic stability, stent fracture incidence, and re-intervention rates in pediatric patients receiving transcatheter pulmonary valve replacement (TPVR) following surgical repair of Tetralogy of Fallot.\n\nMethods: A retrospective analysis of 142 consecutive pediatric patients undergoing TPVR between 2016 and 2025 at Sacred Heart Pediatric Hospital.\n\nResults: Procedural success was achieved in 98.6% of patients with zero intraprocedural mortalities. Freedom from valve failure or re-intervention was 94.2% at 5 years. Cardiac MRI demonstrated marked reduction in right ventricular end-diastolic volume index.\n\nConclusions: TPVR represents a safe, durable, and minimally invasive therapy that preserves right ventricular function in pediatric TOF patients.

Role: Lead Investigator & Corresponding Author
DOI: 10.1016/j.shjpcm.2026.01.004 View Paper
Patient & Physician Inquiries

Get in Touch

For clinical inquiries, second opinions, and medical evaluations with Dr. Marcus Vance.

Direct Office Phone: (850) 288-9974
Office Hours: Mon – Fri: 8:00 AM – 5:00 PM
Submit Patient Request